<p>市场对 <strong>Viking Therapeutics</strong>（VKTX 1.73%）的抗肥胖药物 VK2735 口服制剂的二期试验的顶线结果反应平平。这种失望让人觉得该股票缺乏任何近期的催化剂——VK2735 的皮下（注射）形式的三期结果可能要到 2027 年才能公布——而对该股票的兴奋主要集中在口服制剂上。</p>
<p>然而，这种反应可能过于仓促，投资者仍然有时间买入这只医疗股。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzE3ODcvZ2lybC1pbnZlc3RpbmcuanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzE3ODcvZ2lybC1pbnZlc3RpbmcuanBnJnc9NzAw"/></p>
<p>图片来源：Getty Images。</p>
<h2>Viking Therapeutics 的二期 Venture 试验出了什么问题？</h2>
<p>二期 Venture 口服给药试验显示出令人印象深刻的疗效。然而，投资者对安全性和耐受性数据感到失望，特别是由于不良事件导致的 20% 的停药率。这在这里是一个敏感问题，尤其是 <strong>辉瑞</strong> 在同一类别中也因耐受性数据令人失望而停止了口服减肥药的开发。</p>
<h2>Viking Therapeutics 的下一步在哪里？</h2>
<p>Venture 试验中由于不良反应导致的停药率高于 <strong>礼来</strong> 和 <strong>诺和诺德</strong> 的口服减肥药三期试验中的治疗组。</p>
<table>
<thead>
<tr>
<th>公司</th>
<th>药物</th>
<th>试验</th>
<th>由于不良反应导致的停药率（治疗组）</th>
<th>由于不良反应导致的停药率（安慰剂）</th>
<th>体重减轻</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viking Therapeutics</td>
<td>VK2735（口服）</td>
<td>Venture（二期）</td>
<td>20%</td>
<td>13%</td>
<td>12.2%*</td>
</tr>
<tr>
<td>诺和诺德</td>
<td>semaglutide（口服）</td>
<td>Oasis-1（三期）</td>
<td>6%</td>
<td>4%</td>
<td>15%</td>
</tr>
<tr>
<td>礼来</td>
<td>orforglipron</td>
<td>Attain-1（三期）</td>
<td>10.3%*</td>
<td>2.6%</td>
<td>12.4%*</td>
</tr>
</tbody>
</table>
<p>数据来源：Viking Therapeutics，礼来，心血管教育医师学院。* 在最高剂量下</p>
<p>然而，一家大型制药公司可能会对收购 Viking 或与其合作开发 VK2735 的口服形式感兴趣，并帮助其通过三期测试，或者在优化剂量后将其推进三期。或者，它可以作为已经通过治疗减重的患者的维持治疗。</p>
<p>Viking 可能拥有比市场认为的更多选择。</p>

Viking治疗

<p>Viking Therapeutics（VKTX）针对其抗肥胖药物 VK2735 的第二阶段试验结果令投资者失望，特别是由于不良事件导致的 20% 停药率。尽管存在担忧，分析师认为仍可能存在投资机会，因为大型制药公司可能会收购或与 Viking 合作，以推动 VK2735 进行进一步测试。市场的反应可能过于仓促，因为 Viking 的潜力可能超过目前的认知</p>

<p>The market was less than impressed with the top-line results from <strong>Viking Therapeutics</strong>' (VKTX 1.73%) phase 2 trial of an oral formulation of its anti-obesity drug VK2735. The disappointment created the sense that the stock lacks any near-term catalysts -- phase 3 results from VK2735 in subcutaneous (injection) form aren't likely until 2027 -- and that the excitement around the stock was primarily centered on the oral formulation.</p>
<div class="lb-trans"><p>市场对 <strong>Viking Therapeutics</strong>（VKTX 1.73%）的抗肥胖药物 VK2735 口服制剂的二期试验的顶线结果反应平平。这种失望让人觉得该股票缺乏任何近期的催化剂——VK2735 的皮下（注射）形式的三期结果可能要到 2027 年才能公布——而对该股票的兴奋主要集中在口服制剂上。</p>
</div><p>However, that reaction may prove too hasty, and there's still time to buy into the healthcare stock.</p>
<div class="lb-trans"><p>然而，这种反应可能过于仓促，投资者仍然有时间买入这只医疗股。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzE3ODcvZ2lybC1pbnZlc3RpbmcuanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F831787%2Fgirl-investing.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>What went wrong with Viking Therapeutics' phase 2 Venture trial?</h2>
<div class="lb-trans"><h2>Viking Therapeutics 的二期 Venture 试验出了什么问题？</h2>
</div><p>The phase 2 Venture oral dosing trial demonstrated impressive efficacy. However, investors were left disappointed by the safety and tolerability data, particularly the 20% rate of discontinuation due to adverse events. This is a sensitive issue here, particularly as <strong>Pfizer</strong> discontinued development of an oral weight loss drug in the same class that also had disappointing tolerability data in a trial.</p>
<div class="lb-trans"><p>二期 Venture 口服给药试验显示出令人印象深刻的疗效。然而，投资者对安全性和耐受性数据感到失望，特别是由于不良事件导致的 20% 的停药率。这在这里是一个敏感问题，尤其是 <strong>辉瑞</strong> 在同一类别中也因耐受性数据令人失望而停止了口服减肥药的开发。</p>
</div><h2>Where next for Viking Therapeutics?</h2>
<div class="lb-trans"><h2>Viking Therapeutics 的下一步在哪里？</h2>
</div><p>Discontinuation rates due to adverse effects in the Venture trial were higher than those in treatment groups in phase 3 trials of oral weight loss drugs by <strong>Eli Lilly</strong> and <strong>Novo Nordisk.</strong></p>
<div class="lb-trans"><p>Venture 试验中由于不良反应导致的停药率高于 <strong>礼来</strong> 和 <strong>诺和诺德</strong> 的口服减肥药三期试验中的治疗组。</p>
</div><table>
<thead>
<tr>
<th>Company</th>
<th>Drug</th>
<th>Trial</th>
<th>Discontinuation Rate Due to Adverse Effects (Treated)</th>
<th>Discontinuation Rate Due to Adverse Effects (Placebo)</th>
<th>Body Weight Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viking Therapeutics</td>
<td>VK2735 (oral)</td>
<td>Venture (phase 2)</td>
<td>20%</td>
<td>13%</td>
<td>12.2%*</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td>semaglutide (oral)</td>
<td>Oasis-1 (phase 3)</td>
<td>6%</td>
<td>4%</td>
<td>15%</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>orforglipron</td>
<td>Attain-1 (phase 3)</td>
<td>10.3%*</td>
<td>2.6%</td>
<td>12.4%*</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>公司</th>
<th>药物</th>
<th>试验</th>
<th>由于不良反应导致的停药率（治疗组）</th>
<th>由于不良反应导致的停药率（安慰剂）</th>
<th>体重减轻</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viking Therapeutics</td>
<td>VK2735（口服）</td>
<td>Venture（二期）</td>
<td>20%</td>
<td>13%</td>
<td>12.2%*</td>
</tr>
<tr>
<td>诺和诺德</td>
<td>semaglutide（口服）</td>
<td>Oasis-1（三期）</td>
<td>6%</td>
<td>4%</td>
<td>15%</td>
</tr>
<tr>
<td>礼来</td>
<td>orforglipron</td>
<td>Attain-1（三期）</td>
<td>10.3%*</td>
<td>2.6%</td>
<td>12.4%*</td>
</tr>
</tbody>
</table>
</div><p>Data sources: Viking Therapeutics, Eli Lilly, Physicians Academy for Cardiovascular Education. *At highest dosage</p>
<div class="lb-trans"><p>数据来源：Viking Therapeutics，礼来，心血管教育医师学院。* 在最高剂量下</p>
</div><p>However, a larger pharmaceutical company may be interested in acquiring Viking or partnering with it to develop VK2735 in oral form and help it through phase 3 testing, or, alternatively, take it to phase 3 after optimizing the dosage. Or, it could be used as a maintenance therapy for patients who have already lost weight through treatment.</p>
<div class="lb-trans"><p>然而，一家大型制药公司可能会对收购 Viking 或与其合作开发 VK2735 的口服形式感兴趣，并帮助其通过三期测试，或者在优化剂量后将其推进三期。或者，它可以作为已经通过治疗减重的患者的维持治疗。</p>
</div><p>Viking may have more options than the market thinks.</p>
<div class="lb-trans"><p>Viking 可能拥有比市场认为的更多选择。</p>
</div>

觉得现在买入这只领先的生物科技股票已经太迟了吗？以下是为什么仍然有机会的原因